CoChat

Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure

Bagger, Jonatan Ising, Holst, Jens Juul, Hartmann, Bolette, Andersen, Birgitte, Knop, Filip Krag, Vilsbøll, Tina · 2015 · The Journal of Clinical Endocrinology & Metabolism
Cited by 88

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

CONTEXT: The gut hormone, oxyntomodulin, is a proglucagon product with body weight-lowering potential. It binds to both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor; however, the mechanism behind the body weight-lowering effect remains elusive. OBJECTIVE: We wanted to delineate the contributions of separate and combined GLP-1 receptor and glucagon receptor activation to the body weight-reducing mechanisms of oxyntomodulin. DESIGN: This was a double-blinded, randomized, crossover study. SETTING: The study was conducted at a specialized research unit. PARTICIPANTS: Fifteen young healthy male volunteers (aged 22 [range 18-32] y; body mass index 23 [21-26] kg/m(2); fasting plasma glucose 5.1 [4.4-5.4] mmol/L; and glycated hemoglobin A1c 40 (37-42) mmol/mol). INTERVENTIONS: Five 4-hour liquid meal tests during the infusion of saline, GLP-1 (1 pmol × kg(-1) × min(-1)), glucagon (0.86 pmol × kg(-1) × min(-1)), oxyntomodulin (3 pmol × kg(-1) × min(-1)), or glucagon+GLP-1 (same doses). MAIN OUTCOME MEASURES: We evaluated resting energy expenditure (measured as oxygen uptake, gastric emptying (GE), composite appetite scores (CAS), and food intake. RESULTS: Oxyntomodulin, GLP-1, and GLP-1+glucagon slowed GE and reduced CAS, whereas glucagon did not affect GE and CAS. All infusions caused a similar decrease in food intake compared with saline (total intake (g [95% confidence interval]), saline 811 [729, 892], GLP-1 669 [586, 750], glucagon 686 [604, 768], oxyntomodulin 689 [608, 771], and glucagon+GLP-1 688 [606, 769]). Oxygen uptake did not change significantly from baseline in response to any peptide infusion compared with saline. CONCLUSIONS: Oxyntomodulin, GLP-1, and glucagon decreased food intake but with no additional effect of combining GLP-1 and glucagon.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2015-2335

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 29

  1. Schjoldager, 1988, Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man, Eur J Clin Invest, 18, 499, 10.1111/j.1365-2362.1988.tb01046.x · DOI · Paper page
  2. Dakin, 2001, Oxyntomodulin inhibits food intake in the rat, Endocrinology, 142, 4244, 10.1210/endo.142.10.8430 · DOI · Paper page
  3. Gros, 1993, Glucagon-like peptide-1-(7–36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line, Endocrinology, 133, 631, 10.1210/endo.133.2.8102095 · DOI · Paper page
  4. Baldissera, 1988, Oxyntomodulin (glicentin-(33–69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs, Regul Pept, 21, 151, 10.1016/0167-0115(88)90099-7 · DOI
  5. Holst, 1997, Enteroglucagon, Annu Rev Physiol, 59, 257, 10.1146/annurev.physiol.59.1.257 · DOI · Paper page
  6. Holst, 1983, Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin—current status, Gastroenterology, 84, 1602, 10.1016/0016-5085(83)90388-8 · DOI
  7. Holst, 1982, Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33–69) of glicentin, Biochem J, 207, 381, 10.1042/bj2070381 · DOI · Paper page
  8. Druce, 2009, Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs, Endocrinology, 150, 1712, 10.1210/en.2008-0828 · DOI · Paper page
  9. Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, E981
  10. Penick, 1961, Depression of food intake induced in healthy subjects by glucagon, N Engl J Med, 264, 893, 10.1056/NEJM196105042641801 · DOI · Paper page
  11. Schulman, 1957, Effect of glucagon on food intake and body weight in man, J Appl Physiol, 11, 419, 10.1152/jappl.1957.11.3.419 · DOI · Paper page
  12. Geary, 1992, Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men, Am J Physiol, 262, R975
  13. Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 · DOI · Paper page
  14. Kosinski, 2012, The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin, Obes (Silver Spring Md), 20, 1566, 10.1038/oby.2012.67 · DOI · Paper page
  15. Gregersen, 2008, Reproducibility and power of ad libitum energy intake assessed by repeated single meals, Am J Clin Nutr, 87, 1277, 10.1093/ajcn/87.5.1277 · DOI
  16. Orskov, 1994, Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans, Diabetes, 43, 535, 10.2337/diab.43.4.535 · DOI · Paper page
  17. Albrechtsen, 2014, Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?, Diabetologia, 57, 1919, 10.1007/s00125-014-3283-z · DOI · Paper page
  18. Sloth, 2009, The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period, Br J Nutr, 101, 1846, 10.1017/S0007114508137710 · DOI · Paper page
  19. Van Cauter, 1992, Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance, Diabetes, 41, 368, 10.2337/diabetes.41.3.368 · DOI
  20. Kjems, 2000, Validation of methods for measurement of insulin secretion in humans in vivo, Diabetes, 49, 580, 10.2337/diabetes.49.4.580 · DOI · Paper page
  21. Kjems, 2001, Quantification of β-cell function during IVGTT in type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods, Diabetologia, 44, 1339, 10.1007/s001250100639 · DOI
  22. D'Alessio, 1988, Thermic effect of food in lean and obese men, J Clin Invest, 81, 1781, 10.1172/JCI113520 · DOI · Paper page
  23. Shalev, 1997, Effects of glucagon-like peptide 1 (7–36 amide) on whole-body protein metabolism in healthy man, Eur J Clin Invest, 27, 10, 10.1046/j.1365-2362.1997.540613.x · DOI · Paper page
  24. Tan, 2013, Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia, Diabetes, 62, 1131, 10.2337/db12-0797 · DOI · Paper page
  25. Schmidt, 2014, Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men, Am J Physiol Endocrinol Metab, 306, E1248, 10.1152/ajpendo.00569.2013 · DOI · Paper page
  26. Harder, 2004, The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes, Diabetes Care, 27, 1915, 10.2337/diacare.27.8.1915 · DOI · Paper page
  27. Taylor, 1975, Glucagon and the colon, Gut, 16, 973, 10.1136/gut.16.12.973 · DOI
  28. Dotevall, 1963, The effect of glucagon on intestinal motility in man, Gastroenterology, 45, 364, 10.1016/S0016-5085(19)34888-7 · DOI
  29. Cohen, 2003, Oxyntomodulin suppresses appetite and reduces food intake in humans, J Clin Endocrinol Metab, 88, 4696, 10.1210/jc.2003-030421 · DOI · Paper page

Cited by

See all 88

Metadata

Authors
Bagger, J. I., Holst, J. J., Hartmann, B., Andersen, B., Knop, F. K., & Vilsbøll, T.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2015-12-01
Volume
100
Issue
12
Pages
4541-4552
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2150622862
Cited by
88
References
12
FWCI
3.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. https://app.cochat.ai/papers/10.1210/jc.2015-2335
The paper
Bagger, J. I., Holst, J. J., Hartmann, B., Andersen, B., Knop, F. K., & Vilsbøll, T. (2015). Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2015-2335

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.